美邦股份盘中跌停 上演“天地板”

Group 1 - The core event involves Meibang Co., which experienced a "limit-up" followed by a "limit-down" in its stock price, indicating extreme volatility in trading [2] - As of the report, Meibang Co.'s stock price was at 28.39 yuan per share, with a total market capitalization of 3.8 billion yuan and a trading volume exceeding 700 million yuan, reflecting a turnover rate of over 19% and a price fluctuation of 19.97% [2] - The stock had previously seen a continuous rise, with four consecutive days of limit-up trading, reminiscent of a similar pattern observed in July 2025 [2] Group 2 - Meibang Co. acknowledged that its stock price increase has significantly outpaced the industry index and the Shanghai Composite Index, indicating potential market overreaction and irrational speculation [3] - The company reported a decline in operating revenue for the first three quarters of 2025, amounting to 609 million yuan, a year-on-year decrease of 2.23%, and a net profit attributable to shareholders of 36.2 million yuan, down 16.36% year-on-year [2] - The current price-to-earnings ratio of Meibang Co. is notably higher than that of its industry peers, suggesting characteristics of stock price bubble [3]

Shaanxi Meibang Pharmaceutical -美邦股份盘中跌停 上演“天地板” - Reportify